NAVIDEA BIOPHARMACEUTICALS, INC. 4
4 · NAVIDEA BIOPHARMACEUTICALS, INC. · Filed Sep 4, 2014
Insider Transaction Report
Form 4
Nordlicht Mark
10% Owner
Transactions
- Sale
Common Stock, par value $0.001
2014-09-02$1.36/sh−60,000$81,552→ 14,946,431 total(indirect: By Platinum Partners Value Arbitrage Fund L.P.)
Holdings
- 100,000(indirect: By Platinum Partners Liquid Opportunity Master Fund L.P.)
Common Stock, par value $0.001
Footnotes (3)
- [F1]This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.
- [F3]Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.